SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis
Advanced Science · 2026-04 · 13 (19)
DOI: 10.1002/advs.202522996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.02.2026. Verfasst von Ting Wen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Matrix Attachment Region Binding Proteins, Lung Neoplasms, Lipocalin-2, Histone Deacetylases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Lung cancer remains a leading cause for global cancer‐related mortality, with therapeutic resistance and metastasis posing major clinical challenges. The special AT‐rich sequence‐binding protein 2 (SATB2) is a well‐established tumor suppressor in NSCLC, but its downstream epigenetic and metabolic regulatory mechanisms remain largely unclear. Here, we demonstrate that SATB2 exerts tumor‐suppressive effects by impairing NSCLC cell proliferation, migration, invasion, and EMT. Mechanistically, SATB2 functions as a negative regulator of global histone lactylation, with a specific role in reducing histone H3 lysine 9 lactylation (H3K9la)—a previously uncharacterized histone mark in NSCLC. Through integrated multi‐omics analyses (RNA‐seq and H3K9la‐specific CUT&Tag), we identified Lipocalin‐2 (LCN2), an oncoprotein, as a critical downstream target of the SATB2‐H3K9la axis. SATB2 is able to bind LCN2 promoter and recruit histone deacetylase 3 (HDAC3) via its N‐terminal domain, catalyzing H3K9 delactylation to repress LCN2 transcription. Exogenous lactate reversed SATB2‐mediated H3K9la and LCN2 suppression, restoring oncogenic phenotypes. In vivo, SATB2 overexpression inhibited xenograft tumor growth and lung metastasis, while LCN2 overexpression rescued these suppressive effects. Our findings uncover a novel epigenetic‐metabolic crosstalk pathway in NSCLC, providing new insights into the molecular mechanisms of SATB2‐mediated tumor suppression and potential therapeutic targets for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Centre for Chromosome Biology, School of Natural Sciences, University of Galway, Galway, Ireland.
- Division of Environmental Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
- Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
ORCID-Profile: Qiao Yi Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wen, T., Yang, L., Cai, S., Liu, Y., Fan, J., Wu, P., Gao, B., Xie, X., Sun, H., Qin, S., & Chen, Q. Y. (2026). SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis. Advanced Science, 13(19). https://doi.org/10.1002/advs.202522996
Vancouver
Wen T, Yang L, Cai S, Liu Y, Fan J, Wu P, et al. SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis. Advanced Science. 2026;13(19). doi:10.1002/advs.202522996
BibTeX
@article{Wen2026,
author = {Wen, Ting and Yang, Lihua and Cai, Shuang and Liu, Yunxia and Fan, Jianan and Wu, Peng and Gao, Beibei and Xie, Xiaoge and Sun, Hong and Qin, Sida and Chen, Qiao Yi},
title = {SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {19},
doi = {10.1002/advs.202522996}
}
EUVIMED